Related Experiment Video
Updated: Oct 12, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid
B J Powell1, J L Campbell, J F Landon
1Kansas City Veterans Administration Medical Center (151), Kansas City 64128, USA.
Abstract:
This double-blind, placebo-controlled, 6-month follow-up treatment study investigated the efficacy of bromocriptine and nortriptyline in attenuating drinking behavior and psychiatric symptoms in 216 male alcoholic patients subtyped by comorbid psychiatric disorder(s). Three well-defined subtypes were examined: alcoholism only, alcoholism + affective/anxiety disorder, and alcoholism + antisocial personality disorder. It was hypothesized that both medications would relieve negative affective symptoms associated with alcohol use and would be particularly effective for the affective/anxiety subgroup. Contrary to our predictions, the only significant effects found were with the antisocial personality disorder patients who were receiving nortriptyline. One interpretation of the results was that nortriptyline may have reduced impulsive drinking in the antisocial personality disorder subgroup by actions on serotonergic neurotransmission.
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Alcohol and Nicotine
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents

